Epidemiology and Impact of Hidradenitis Suppurativa

Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women were found to potentially benefit from higher calcium consumption.

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a potentially cost-effective access point to dermatological care.

Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.